STAGE [9], FILM [10], and FEATURE [11] studied ocrelizumab in RA patients on stable MTX who had inadequate responses to MTX, while SCRIPT [12] studied ocrelizumab in RA patients taking MTX or leflunomide who had inadequate responses to at least one TNF antagonist. This evidence concerns the gene TNF and rheumatoid arthritis.